Authors
Latest:
Dr. Uy on the Efficacy Findings from a Phase 1/2 Trial in R/R AMLGeoffrey L. Uy, MD, discusses the efficacy findings from a phase 1/2 trial in relapsed/refractory acute myeloid leukemia.
Latest:
Closing Thoughts on the MDS Treatment LandscapeFollowing its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.
Latest:
Dr. Markowski on the Evaluation of Sabizabulin in mCRPCMark C. Markowski, MD, PhD, discusses the evaluation of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate cancer.
Latest:
The AACR Releases a Call to Action and Key Statistics in Cancer Disparities Progress Report 2024The AACR issues a call to action and cites progress, needed improvements, and key statistics in their Cancer Disparities Progress Report 2024.
Latest:
Dr. Ghodoussipour on Trials of Cytoreductive Surgery in Metastatic RCC and Prostate CancerSaum Ghodoussipour, MD, discusses ongoing trials in renal cell carcinoma and prostate cancer.
Latest:
Treatment Option for Adult Patients with 3L+ Relapsed or Refractory Diffuse Large B-Cell LymphomaMany people living with diffuse large B-cell lymphoma (DLBCL) continue to experience significant treatment challenges. Genmab and AbbVie discuss the current DLBCL treatment landscape and an effort as part of a collaboration between the two companies for people diagnosed with relapsed or refractory DLBCL.
Latest:
Dr. Caimi on the FDA Approval of Loncastuximab Tesirine in R/R Large B-Cell LymphomaPaolo F. Caimi, MD, discusses the FDA approval of loncastuximab tesirine-lpyl in relapsed/refractory large B-cell lymphoma.
Latest:
Final Overall Survival Data From a Randomized, Open-Label, Phase 2 Study of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Patients With Recurrent Platinum-Resistant Ovarian CancerDomenica Lorusso, MD, PhD, presents the final overall survival data from the randomized open -label phase 2 trial of relacorilant, a selective glucocorticoid receptor modulator in combination with nab-paclitaxel versus nab-paclitaxel alone in patients with recurrent platinum resistant ovarian cancer.
Latest:
Dr. Sam on Sequencing Tucatinib and Trastuzumab Deruxtecan in HER2+ Breast CancerChristine Sam, MD, discusses strategies for sequencing tucatinib and fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive breast cancer.
Latest:
$3.3 Million Grant to IU Researchers Aims to Increase Colorectal Cancer Screening in Rural IndianaResearchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are addressing the low colorectal cancer screening rates in rural Indiana communities with a five-year, $3.3 million grant from the National Cancer Institute.
Latest:
Dr Asare on an AI Model to Predict PFS Outcomes in Ovarian CancerAmma Asare, MD, PhD on the use of AI for predicting PFS in ovarian cancer
Latest:
Dr. Ip on the Utility of Investigational Treatments for COVID-19 in OncologyAndrew Ip, MD, MS, discusses the utility of investigational treatments for COVID-19 in patients with cancer.
Latest:
Dr Sommerhalder on the Potential Utility of Single-Agent RMC-6291 in KRAS G12C–Mutant CRCDavid Sommerhalder, MD, discusses the potential for RMC-6291 as a single agent in KRAS G12C–mutated advanced colorectal cancer.
Latest:
Dr. Liu on Enrolling Diverse Patients in the PREEMPT-CRC Trial in CRCJulia Liu, MD, discusses enrolling diverse patients in the PREEMPT CRC trial in colorectal cancer.
Latest:
Dr Cannon on the Use of Dendritic Cell Vaccines in Ovarian CancerMartin Cannon, PhD, discusses the use of dendritic cell vaccines and immune checkpoint inhibitors in ovarian cancer.
Latest:
Bagley Summarizes the ACTION trial of ONC201 in H3 K27M–Mutant Diffuse Midline GliomasDr Bagley discusses the evaluation of the small molecule ONC201 in the phase 3 ACTION trial in H3 K27M–mutant diffuse midline gliomas.
Latest:
Dr. Hillmen on Results With Acalabrutinib in CLLPeter Hillmen, MD, PhD, discusses results reported with acalabrutinib in patients with chronic lymphocytic leukemia, as demonstrated in a phase 3 trial.
Latest:
Dr Machtay on the Prognostic Value of Pre-Treatment Immunologic Biomarker Levels in NSCLCMitchell Machtay, MD, discusses the association between the levels of circulating immune biomarkers prior to immunotherapy and survival outcomes in patients with stage III non-small cell lung cancer.
Latest:
Dr Bhatnagar on Survival Outcomes With MRD Negativity in AMLBhavana “Tina” Bhatnagar, DO, discusses the investigation of minimal residual disease negativity in patients with acute myeloid leukemia.
Latest:
Montefiore Einstein Comprehensive Cancer Center Awarded FDA Grant for Clinical Trial on Experimental AML/MDS TreatmentLeading researchers in rare blood cancers to investigate new therapeutic strategy that targets leukemic stem cells.
Latest:
Dr Franco on the Integration of Immunotherapy Treatment in Endometrial CancerIdalid Franco, MD, MPH, discusses the use of radiation therapy and immunomodulatory agents in the treatment of endometrial cancer.
Latest:
Dr Hayek on Laparoscopic vs Open Surgery in Advanced Ovarian CancerJudy Hayek, MD, discusses outcomes with minimally invasive vs open interval complete gross resection in patients with advanced ovarian cancer.
Latest:
Future Directions for the Management of HR+ Breast CancerAndrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.
Latest:
Dr Laccetti on PSA Responses With Masofaniten Plus Enzalutamide in mCRPCAndrew Laccetti, MD, MS, discusses phase 1 findings from a phase 1/2 trial investigating masofaniten in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer.
Latest:
Dr. Sood on Navigating Frontline Maintenance Therapy in Ovarian CancerAnil K. Sood, MD, discusses navigating frontline maintenance therapy in ovarian cancer.
Latest:
Overall Survival After Surgery for Spinal Metastases Has Improved Over the Past Two DecadesPostoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.
Latest:
Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple MyelomaSusan Bal, MD, discusses updated safety and efficacy data from a phase 1 study evaluating the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, including in patients with prior BCMA-directed therapy.
Latest:
Dr Coupe on the Background of IMM60 With Pembrolizumab in Melanoma or NSCLCNicholas Coupe, MBBS, PhD, discusses the rationale for investigating IMM60 with pembrolizumab in patients with advanced melanoma or metastatic non-small cell lung cancer, as well as key background information that led to this investigation.
Latest:
A Breakthrough for the “Lab Brat”Building on research his father conducted decades earlier, Robert Orlowski, MD, PhD, redefined myeloma treatment.
